<DOC>
	<DOCNO>NCT00608907</DOCNO>
	<brief_summary>The primary purpose Phase I study evaluate effect co-administration CYP3A4 inducer pharmacokinetics profile VELCADE ( bortezomib ) . Rifampicin use assess effect strong CYP3A4 inducer dexamethasone ass effect relatively weak inducer . This study also evaluate impact CYP3A4 inducer pharmacodynamics ( PD ) VELCADE safety profile VELCADE .</brief_summary>
	<brief_title>An Open-Label Study Assess Effect CYP3A4 Induction Pharmacokinetics VELCADE ( Bortezomib )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Male female least 18 year age . Has document relapse refractory multiple myeloma NHL follow prior antineoplastic treatment . Female patient must post menopausal least 1 year ( must natural menses least 12 month ) , surgically sterile , abstinent , , sexually active , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study ; negative serum Î²HCG negative urine pregnancy test screening . ( alternative oral contraceptive use patient randomized Arm B rifampicin ) . Male patient must agree use acceptable method contraception ( female partner list ) duration study . Must able swallow capsules/tablets whole ( without chewing , crush , open ) . Agree refrain use methylxanthinecontaining product , include caffeine ( e.g. , chocolate bar beverage , coffee , tea , cola ) , Day 11 Cycles 2 3 . Agree refrain use product contain nicotine , alcohol , quinine , grapefruit juice , Seville oranges 7 day first administration VELCADE completion 72hour PK blood sample collection ( post Day 11 VELCADE dose ) Cycle 3 . Diagnosis treatment malignancy multiple myeloma NHL within 1 year randomization , previously diagnose malignancy multiple myeloma NHL radiographic biochemical marker evidence malignancy . History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurological , psychiatric , metabolic disturbance . Known suspect hypersensitivity intolerance rifampicin and/or antibiotic , corticosteroid , boron mannitol . Peripheral neuropathy neuropathic pain Grade 2 high . Preplanned surgery procedure would interfere conduct study major surgery within 2 week randomization . History disallowed therapy : Prior treatment VELCADE . Any drug agent inhibit ( e.g. , cimetidine , erythromycin , fluoxetine , ketoconazole , paroxetine ) induce ( e.g. , carbamazepine , glucocorticoid , phenobarbital , phenytoin , St. John 's Wort ) CYP2C19 CYP3A4 within 28 day first administration VELCADE . Any exposure rifampicin corticosteroid within 28 day screen . Have receive investigational agent use investigational medical device within 28 day plan start treatment . Concurrent participation nontreatment study allow , interfere participation study . Female patient pregnant breastfeeding . Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>